ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Other Events

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Other Events

Story continues below

Item8.01 Other Events.

On January25, 2017, Aldeyra Therapeutics, Inc. (Aldeyra) issued a
press release that provided an update on Aldeyras clinical
development plans. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

Item9.01.Financial Statements and Exhibits.


(d)
Exhibits


Exhibit No.


Description

99.1 Press Release of Aldeyra Therapeutics, Inc. dated January 25,
2017.


About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information

ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.15 at 5.70 with 2,716 shares trading hands.

An ad to help with our costs